<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767776</url>
  </required_header>
  <id_info>
    <org_study_id>18CH050</org_study_id>
    <secondary_id>2019-004425-25</secondary_id>
    <nct_id>NCT04767776</nct_id>
  </id_info>
  <brief_title>Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.</brief_title>
  <acronym>RICHAR2</acronym>
  <official_title>Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X.&#xD;
      Bleeding events related to rivaroxaban are the consequence of physiopathologic,&#xD;
      pharmacokinetic issues or poisoning. A recent study, in healthy subjects, shows that&#xD;
      activated charcoal can reduce significantly exposition to rivaroxaban. However, no results&#xD;
      are available on the minimal dose of activated charcoal necessary in rivaroxaban poisoning.&#xD;
      The objective of this study is to evaluate the effect of 4 dosing regimen activated charcoal&#xD;
      on rivaroxaban pharmacokinetics. It corresponds to a randomised open trial with an incomplete&#xD;
      cross over design (3 occasions). It will enrol 12 healthy subjects. Four treatments&#xD;
      modalities will be studied: rivaroxaban with 50g, 24g, 12g and 6g of activated charcoal&#xD;
      administrated 3 hours after rivaroxaban intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma concentrations of rivaroxaban</measure>
    <time_frame>1, 2, 2.5, 3, 3.5, 4, 5, 7, 9, 12, 24 hours after rivaroxaban administration</time_frame>
    <description>rivaroxaban pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 hour after rivaroxaban administration</time_frame>
    <description>Analysis adverse events related to the administration of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; rivaroxaban and 6 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 12 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 50 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; rivaroxaban and 12 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 6 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 24 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; rivaroxaban and 50 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 24 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 6 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; rivaroxaban and 24 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 50 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)&#xD;
Period &quot; rivaroxaban and 12 milligram of activated charcoal &quot;&#xD;
Washout period (6 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>rivaroxaban 40 mg/day (1 day).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Activated charcoal</intervention_name>
    <description>Activated charcoal 2 hours after rivaroxaban administration (1 day).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Affiliated or beneficiary of a social security category&#xD;
&#xD;
          -  Having signed the inform consent form&#xD;
&#xD;
          -  Having signed the biologic consent form&#xD;
&#xD;
          -  Men aged between 18 and 40 years&#xD;
&#xD;
          -  Weight between 55 and 92 kilogram&#xD;
&#xD;
          -  normal clinical exam&#xD;
&#xD;
          -  normal biological exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication to rivaroxaban&#xD;
&#xD;
          -  Contra-indication to activated charcoal&#xD;
&#xD;
          -  With a history of hemorrhagic disease&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Organic lesion likely to bleed&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  Severe kidney failure&#xD;
&#xD;
          -  Gastroduodenal ulcers&#xD;
&#xD;
          -  Any medication taken during the week prior to the start of the study&#xD;
&#xD;
          -  Consumption of grapefruit juice&#xD;
&#xD;
          -  Routine ingestion of excessive amounts of coffee, tea, chocolate and/or caffeinated&#xD;
             beverages&#xD;
&#xD;
          -  Practice of violent sports&#xD;
&#xD;
          -  Fructose intolerance&#xD;
&#xD;
          -  Glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency syndrome&#xD;
&#xD;
          -  Notable medical history (cardiovascular pathology, pulmonary, neurology ...)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick MISMETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edouard OLLIER, MD</last_name>
    <phone>(0)477829512</phone>
    <phone_ext>+33</phone_ext>
    <email>edouard.ollier@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>(0)477120469</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Patrick Mismetti, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Bertoletti, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Moulin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Accassat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CÃ©cile Duvillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard Ollier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban,</keyword>
  <keyword>Activated charcoal</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Poisoning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

